STOCK TITAN

Kaya Hldgs Inc SEC Filings

KAYS OTC Link

Welcome to our dedicated page for Kaya Hldgs SEC filings (Ticker: KAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Kaya Holdings, Inc. (OTCQB: KAYS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as a fully reporting US public company. Through documents such as Forms 10-K, 10-Q and 8-K, Kaya Holdings reports information about its operations in psilocybin treatment services, medical and recreational cannabis, and its evolving digital assets and cryptocurrency strategy.

Current reports on Form 8-K for KAYS include disclosures about material events such as the engagement of Greentree Financial Group and Conduit Advisors to assist with the development of a cryptocurrency operating subsidiary and Digital Assets Treasury (DAT) strategy, and the execution of debt reduction and debt conversion agreements that resulted in a change in control when a major creditor obtained majority voting power. These filings provide detail on capital structure changes, financing relationships and strategic initiatives that complement the company’s press releases.

Investors can also review notifications of late filing on Form 12b-25, which explain timing considerations around the preparation, certification and review of quarterly financial statements. Together with periodic reports, these filings help clarify how Kaya Holdings accounts for its psilocybin treatment center operations through Fifth Dimension Therapeutics, cannabis-related subsidiaries, and planned digital asset activities.

On Stock Titan, KAYS filings are updated as they are released on EDGAR, and AI-powered tools can assist in summarizing lengthy documents, highlighting key sections on topics such as changes in control, segment descriptions, risk factors, and capital structure. Users can quickly locate relevant 8-Ks, 10-Qs, 10-Ks and other forms to understand how Kaya Holdings describes its business, reports its financial condition, and discloses material events to regulators and the market.

Rhea-AI Summary

Kaya Holdings, Inc. reported a board change, appointing Richard D. Seay as a director effective November 25, 2025. Mr. Seay, age 72, is a licensed attorney who has practiced law for 47 years in Florida state and federal courts and has operated his own firm in Fort Lauderdale for at least the past five years.

His background includes work as a state prosecutor, in-house counsel, and in managerial and supervisory roles at public companies, with practice areas covering commercial and civil litigation, securities, and corporate and business law. The board believes his broad legal and business experience makes him a valuable addition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Kaya Holdings (KAYS)$199,358, while total liabilities were $2,919,815, leaving a stockholders’ deficit of $2,720,457, improved from a deficit of $17.1 million at December 31, 2024 mainly due to large debt conversions to equity and derecognition of derivative liabilities.

For the nine months, net sales rose to $22,557 from $3,000 a year earlier, but the business remained far from scale. The company posted a net loss of $12,774,232 versus $3,243,797 in the prior-year period, driven largely by a $10,985,435 non-cash expense from changes in derivative liabilities and significant interest and discount amortization on convertible notes.

Cash was only $26,087, and the company used $459,666 in operating cash flows while raising $420,000 from new convertible notes. Management discloses a working capital deficiency of $2,422,383 and states that these conditions raise substantial doubt about its ability to continue as a going concern. The company has exited cannabis retail, sold its last OLCC license, and now focuses on psychedelic treatment operations through its Sacred Mushroom psilocybin service center.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
quarterly report
-
Filing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Kaya Holdings (KAYS) announced a major balance sheet move, converting over 90% of its outstanding debt into equity. The Company issued 642,868,838 shares of common stock to satisfy $13,979,148 of debt.

CVC International Ltd. received 581,914,466 of those shares in exchange for $11,638,289 in principal and interest on its convertible notes. CVC now holds approximately 56.19% of the Company’s voting power, which constitutes a change in control.

The conversion was undertaken to improve the capital structure in connection with KAYS’s planned development of a cryptocurrency subsidiary and potential digital assets treasury strategy, as referenced in a contemporaneous press release.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report
-
Rhea-AI Summary

Kaya Holdings, Inc. reported that on September 17, 2025 it engaged Greentree Financial Group, Inc. and Conduit Advisors, LLC to help create a new cryptocurrency-focused operating subsidiary. Through this subsidiary, the company plans to develop, launch and implement a Digital Assets Treasury (DAT) strategy and related cryptocurrency operations, signaling an effort to expand its activities into digital assets. The engagement was disclosed via a press release attached as an exhibit.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
current report

FAQ

What is the current stock price of Kaya Hldgs (KAYS)?

The current stock price of Kaya Hldgs (KAYS) is $0.0372 as of February 26, 2026.

What is the market cap of Kaya Hldgs (KAYS)?

The market cap of Kaya Hldgs (KAYS) is approximately 831.3K.

KAYS Rankings

KAYS Stock Data

831.29k
667.42M
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Boca Raton

KAYS RSS Feed